| P50 | author | David Hevia | Q56936548 |
| | Pedro Gonzalez-Menendez | Q103823000 |
| | Juan C. Mayo | Q44472053 |
| | Rosa María Sainz | Q41573073 |
| P2860 | cites work | Testosterone and DHEA activate the glucose metabolism-related signaling pathway in skeletal muscle | Q46694902 |
| | Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts | Q46879124 |
| | Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid | Q49140908 |
| | Testosterone increases GLUT4-dependent glucose uptake in cardiomyocytes. | Q50916859 |
| | The expression pattern of the glucose transporter GLUT-5 in the testis during the spermatogenic cycle of the vespertilionid bat Scotophilus heathi. | Q50920988 |
| | Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. | Q53167532 |
| | Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by modulating the expression of GLUT1, GLUT3, PFK, LDH and MCT4 genes. | Q53476667 |
| | Roles of facilitative glucose transporter GLUT1 in [18F]FDG positron emission tomography (PET) imaging of human diseases | Q56835831 |
| | Hallmarks of Cancer: The Next Generation | Q22252312 |
| | Understanding the Warburg effect: the metabolic requirements of cell proliferation | Q24604760 |
| | Glucose metabolism attenuates p53 and Puma-dependent cell death upon growth factor deprivation | Q24643422 |
| | Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells | Q24648994 |
| | Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression | Q24654019 |
| | Targeting the androgen receptor in prostate and breast cancer: several new agents in development | Q27009424 |
| | Structural basis for substrate transport in the GLUT-homology family of monosaccharide transporters | Q27684502 |
| | On the Origin of Cancer Cells | Q27861025 |
| | Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 |
| | Oncometabolites: tailoring our genes | Q28085392 |
| | Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland | Q28140600 |
| | Germline mutations in HOXB13 and prostate-cancer risk | Q28257179 |
| | Erythrocyte Glut1 triggers dehydroascorbic acid uptake in mammals unable to synthesize vitamin C | Q28273605 |
| | A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death | Q28300548 |
| | Regulation of cancer cell metabolism | Q28303890 |
| | The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression | Q28609179 |
| | The biology of cancer: metabolic reprogramming fuels cell growth and proliferation | Q29547301 |
| | Tumor cell metabolism: cancer's Achilles' heel | Q29619809 |
| | Inhibition of GLUT4 translocation by Tbc1d1, a Rab GTPase-activating protein abundant in skeletal muscle, is partially relieved by AMP-activated protein kinase activation | Q30439894 |
| | Inositol hexaphosphate inhibits tumor growth, vascularity, and metabolism in TRAMP mice: a multiparametric magnetic resonance study | Q30580227 |
| | Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality | Q33668168 |
| | Regulation of the pentose phosphate pathway by an androgen receptor-mTOR-mediated mechanism and its role in prostate cancer cell growth. | Q33672445 |
| | Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies | Q34081705 |
| | Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test | Q34126444 |
| | Novel therapies for metastatic castrate-resistant prostate cancer | Q34249263 |
| | Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. | Q34274098 |
| | Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. | Q44816778 |
| | p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation | Q45345446 |
| | Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer | Q46590858 |
| | Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile | Q34298773 |
| | The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism | Q34332654 |
| | The Warburg Effect: How Does it Benefit Cancer Cells? | Q34509467 |
| | Metformin--mode of action and clinical implications for diabetes and cancer | Q34658712 |
| | Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues | Q34703441 |
| | ATM and GLUT1-S490 phosphorylation regulate GLUT1 mediated transport in skeletal muscle | Q34776170 |
| | Diabetes protects from prostate cancer by downregulating androgen receptor: new insights from LNCaP cells and PAC120 mouse model | Q34994538 |
| | Interactions of androgens, green tea catechins and the antiandrogen flutamide with the external glucose-binding site of the human erythrocyte glucose transporter GLUT1. | Q35045733 |
| | Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis | Q35183953 |
| | Targeting prostate cancer cell metabolism: impact of hexokinase and CPT-1 enzymes. | Q35514392 |
| | Characterization of KRAS rearrangements in metastatic prostate cancer | Q35581673 |
| | Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer | Q35842210 |
| | Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. | Q35897181 |
| | Molecular characterization of Gleason patterns 3 and 4 prostate cancer using reverse Warburg effect-associated genes | Q36010440 |
| | Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism | Q36319414 |
| | The Emerging Hallmarks of Cancer Metabolism | Q36468964 |
| | Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activation | Q36544603 |
| | Mitochondrial oncobioenergetic index: A potential biomarker to predict progression from indolent to aggressive prostate cancer | Q36619120 |
| | Extranuclear Actions of the Androgen Receptor Enhance Glucose-Stimulated Insulin Secretion in the Male | Q36892733 |
| | Heterogeneity of tumor-induced gene expression changes in the human metabolic network | Q36927094 |
| | Caveolin-1-LRP6 signaling module stimulates aerobic glycolysis in prostate cancer | Q36944221 |
| | The metabolic co-regulator PGC1α suppresses prostate cancer metastasis. | Q36944849 |
| | Insulin: a novel agent in the pathogenesis of prostate cancer | Q37229843 |
| | Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer | Q37348599 |
| | PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer | Q37390670 |
| | AMP-activated protein kinase promotes human prostate cancer cell growth and survival | Q37415957 |
| | Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches | Q37537958 |
| | Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling | Q37648017 |
| | Sugar-free approaches to cancer cell killing | Q37802748 |
| | Androgens, diabetes and prostate cancer | Q38003588 |
| | Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer | Q38122948 |
| | N-glycosylation is critical for the stability and intracellular trafficking of glucose transporter GLUT4 | Q38418322 |
| | Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells. | Q38480518 |
| | BRAF and KRAS mutations in prostatic adenocarcinoma | Q38510108 |
| | p53 in survival, death and metabolic health: a lifeguard with a licence to kill | Q38540071 |
| | AMPK: An Energy-Sensing Pathway with Multiple Inputs and Outputs | Q38652124 |
| | Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment | Q38698728 |
| | Metabolic targets for potential prostate cancer therapeutics | Q38747245 |
| | Testosterone insulin-like effects: an in vitro study on the short-term metabolic effects of testosterone in human skeletal muscle cells | Q38784181 |
| | A Protein Kinase C Phosphorylation Motif in GLUT1 Affects Glucose Transport and is Mutated in GLUT1 Deficiency Syndrome | Q38873906 |
| | Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis | Q38886238 |
| | A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy | Q38886986 |
| | Melatonin uptake through glucose transporters: a new target for melatonin inhibition of cancer | Q38917542 |
| | Regulation of GLUT transporters by flavonoids in androgen-sensitive and -insensitive prostate cancer cells | Q38984366 |
| | Cancer Statistics, 2017. | Q39038674 |
| | Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch. | Q39067480 |
| | Tumor necrosis factor alpha increases aerobic glycolysis and reduces oxidative metabolism in prostate epithelial cells | Q39131885 |
| | Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. | Q39149779 |
| | Glucose Metabolism in the Progression of Prostate Cancer | Q39167169 |
| | Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading | Q39301749 |
| | A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. | Q39332797 |
| | The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis | Q39538459 |
| | AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. | Q39542812 |
| | miR-132 mediates a metabolic shift in prostate cancer cells by targeting Glut1. | Q39615767 |
| | CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells | Q39628801 |
| | Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer | Q39634850 |
| | Small compound inhibitors of basal glucose transport inhibit cell proliferation and induce apoptosis in cancer cells via glucose-deprivation-like mechanisms | Q39672602 |
| | Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells | Q39730167 |
| | Hypoxia and the metabolic phenotype of prostate cancer cells | Q39838371 |
| | Expression and localization of hypoxia proteins in prostate cancer: prognostic implications after radical prostatectomy | Q39935802 |
| | Insulin receptor expression by human prostate cancers | Q39941083 |
| | Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapy | Q39944174 |
| | GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications | Q41339288 |
| | Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue | Q42494827 |
| | Testosterone stimulates glucose uptake and GLUT4 translocation through LKB1/AMPK signaling in 3T3-L1 adipocytes. | Q42825923 |
| | Prostate cancer risk and serum levels of insulin and leptin: a population-based study | Q43608448 |
| | Expression and localization of GLUT1 and GLUT12 in prostate carcinoma | Q44389314 |
| P407 | language of work or name | English | Q1860 |
| P577 | publication date | 2017-11-21 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | The dark side of glucose transporters in prostate cancer: Are they a new feature to characterize carcinomas? | |